(NASDAQ: TNGX) Tango Therapeutics's forecast annual revenue growth rate of 1.25% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Tango Therapeutics's revenue in 2024 is $36,527,000.On average, 5 Wall Street analysts forecast TNGX's revenue for 2024 to be $3,157,154,631, with the lowest TNGX revenue forecast at $2,241,084,615, and the highest TNGX revenue forecast at $4,503,512,893. On average, 4 Wall Street analysts forecast TNGX's revenue for 2025 to be $3,762,887,787, with the lowest TNGX revenue forecast at $2,667,957,875, and the highest TNGX revenue forecast at $6,157,646,776.
In 2026, TNGX is forecast to generate $3,978,992,375 in revenue, with the lowest revenue forecast at $2,667,957,875 and the highest revenue forecast at $7,022,065,127.